REAKSI SAHAM SEKTOR FARMASI DI BURSA EFEK INDONESIA TERHADAP VAKSINASI COVID-19 PERTAMA PRESIDEN JOKO WIDODO
on
Authors:
Ni Kadek Sukma Dwiyantika, Gerianta Wirawan Yasa
Abstract:
“This study aims to determine the reaction of pharmaceutical sector stocks to President Joko Widodo’s first Covid-19 vaccination. The number of samples in this study were 18 companies, the sampling technique used non-probability sampling with saturated sampling method. The data analysis technique used is an event study with a hypothesis testing tool using the One Sample t-Test. The results of this study indicate that there are differences in abnormal returns before and after the administration of President Joko Widodo’s first Covid-19 vaccination, where there was a positive reaction before the administration of the first Covid-19 vaccination to President Joko Widodo and a negative reaction at the time of administration on January 13, 2021 and after President Joko Widodo’s first Covid-19 vaccination. This shows that it is important for investors to observe critically when absorbing and responding to signals, especially when making investment decisions.”
Keywords
Keyword Not Available
Downloads:
Download data is not yet available.
References
References Not Available
PDF:
https://jurnal.harianregional.com/eeb/full-86628
Published
2023-08-31
How To Cite
SUKMA DWIYANTIKA, Ni Kadek; WIRAWAN YASA, Gerianta. REAKSI SAHAM SEKTOR FARMASI DI BURSA EFEK INDONESIA TERHADAP VAKSINASI COVID-19 PERTAMA PRESIDEN JOKO WIDODO.E-Jurnal Ekonomi dan Bisnis Universitas Udayana, [S.l.], p. 1520-1528, aug. 2023. ISSN 2337-3067. Available at: https://ojs.unud.ac.id/index.php/EEB/article/view/86628. Date accessed: 28 Aug. 2025. doi:https://doi.org/10.24843/EEB.2023.v12.i08.p06.
Citation Format
ABNT, APA, BibTeX, CBE, EndNote - EndNote format (Macintosh & Windows), MLA, ProCite - RIS format (Macintosh & Windows), RefWorks, Reference Manager - RIS format (Windows only), Turabian
Issue
VOLUME.12.NO.08.TAHUN.2023
Section
Articles
Copyright
This work is licensed under a Creative Commons Attribution 4.0 International License
Discussion and feedback